NEW YORK (Reuters) Jul 09 –
Shares of US drugmaker Wyeth tumbled on Tuesday after a study showed that women taking Prempro, the company’s hugely popular hormone replacement drug, had an increased risk of breast cancer, stroke, and heart disease.
The large federal study involved the combination pill, which contains the female hormone estrogen as well as another female hormone called progestin. In 2001, it accounted for about $890 million of Wyeth’s $13.9 billion in sales, according to Steven Tighe, an analyst at Merrill Lynch.
.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!